OOIR: Observatory of International Research

Papers

(The median citation count of Current Opinion in Lipidology is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
Angiopoietin-like protein 8: a multifaceted protein instrumental in regulating triglyceride metabolism	58
Alveolar macrophages: guardians of the alveolar lipid galaxy	58
Genetic variation in apolipoprotein A-V in hypertriglyceridemia	57
Ups and downs in PCSK9 inhibition in the cardiovascular arena: a review	56
Editorial introductions	43
Familial hypercholesterolemia-Plus: is the metabolic syndrome changing the clinical picture of familial hypercholesterolemia?	39
ANGPTL4: a new mode in the regulation of intravascular lipolysis	36
Sphingomyelins and ceramides: possible biomarkers for dementia?	35
Triglyceride-rich lipoproteins, remnant-cholesterol, and atherosclerotic cardiovascular disease	33
Implementation science and genetic testing for familial hypercholesterolemia	32
The lipid-heart hypothesis from the Seven Countries Study of Cardiovascular Diseases	31
Lipoprotein(a) and peripheral artery disease: contemporary evidence and therapeutic advances	30
Oxidized LDL receptors: a recent update	29
Universal screening for familial hypercholesterolaemia: how can we maximise benefits and minimise potential harm for children and their families?	29
Familial hypercholesterolemia: The nexus of endothelial dysfunction and lipoprotein metabolism in COVID-19	28
Exosomes and lipid metabolism in metabolic and cardiovascular disorders	25
Lipid metabolism during pregnancy: consequences for mother and child	22
Familial hypercholesterolemia in children and the importance of early treatment	21
Editorial introductions	19
Nonalcoholic fatty liver disease: an update	18
Genetic determinants of pancreatitis risk in hypertriglyceridemia	17
Familial hypercholesterolemia in pregnancy	17
A new SPRING in lipid metabolism	16
The current state of apolipoprotein E in dyslipidemia	16
Inhibition of angiopoietin-like 3 for the management of severe hypercholesterolemia	15

Splice correction therapies for familial hypercholesterolemic patients with low-density lipoprotein receptor mutations	15
ANGPTL3 and ApoC-III inhibitors for treating hypertriglyceridemia in context: horses for courses?	14
Nutrition and its impact on cardiovascular disease	14
From clinical development to real-world outcomes with inclisiran	14
APOE and familial hypercholesterolemia	14
The need for national and international registries of patients with elevated lipoprotein(a)	14
High-density lipoprotein functionality, cardiovascular health, and patterns of alcohol consumption: new insights and future perspectives	14
Are the lipid-lowering effects of incretin-based therapies relevant for cardiovascular benefit?	13
Beyond cholesterol: linking the conformation of apolipoprotein B to atherogenesis	13
Can small dense LDL cholesterol be estimated from the lipid profile?	13
Inclisiran: present and future perspectives of a new effective LDL cholesterol-lowering agent	13
The intracellular chylomicron highway: novel insights into chylomicron biosynthesis, trafficking, and secretion	13
Cardiomyocytes, sphingolipids and cardio myotoxicity	12
Distinct roles of size-defined HDL subpopulations in cardiovascular disease	12
The emerging role of fat-inducing transcript 2 in endoplasmic reticulum proteostasis and lipoprotein biogenesis	12
Newborn screening for lipid disorders	12
Editorial introductions	11
The expanding role of lyso-phosphatidylcholine acyltransferase-3 (LPCAT3), a phospholipid remodeling enzyme, in health and disease	11
Altered cardiovascular risk pattern of LDL cholesterol in older adults	10
Recent dynamic studies of the metabolism of atherogenic lipoproteins: elucidating the mode of action of new therapies	10
Pregnancy, cardiovascular health, and microchimerism	10
Genetic testing for familial hypercholesterolemia	10
Preprint servers in lipidology: current status and future role	9
Clinical associations between exercise and lipoproteins	9
Association of dietary patterns and components with atherosclerosis risk biomarkers in familial hypercholesterolemia	9
Circulating protein and lipid markers of early sepsis diagnosis and prognosis: a scoping review	9
Strategies for management of patients with elevated lipoprotein(a)	9
Prevention of cardiometabolic diseases through dietary modifications	8
Sphingosine-1-phosphate: metabolism, transport, atheroprotection and effect of statin treatment	8
Genotype–phenotype correlation in a large cohort of pediatric patients with heterozygous and homozygous familial hypercholesterolemia	8
The pathophysiology of excess plasma-free cholesterol	8
Assessment of cardiovascular disease risk: a 2023 update	7
The feedback cycles between glucose, amino acids and lipids and alpha cell secretion and their role in metabolic fatty liver disease	7
Lipidomics in gestational diabetes mellitus	7
Editorial introductions	7
Navigating variants of uncertain significance in genetic dyslipidemia: how to assess and counsel patients	7
A contemporary snapshot of familial hypercholesterolemia registries	7
Dietary fat, telomere length and cognitive function: unravelling the complex relations	6
Clonal hematopoiesis of indeterminate potential and the evolutionary lottery in chromosome 2: does that make human atherosclerosis special?	6
Atherogenic low-density lipoprotein and cardiovascular risk	6
Recent lipoprotein(a) trials	6
How should low-density lipoprotein cholesterol be calculated in 2022?	5
Predictors of cardiovascular risk in familial hypercholesterolemia	5
Understanding the ins and outs of lipoprotein (a) metabolism	5
Are Lipoprotein(a) levels decreased in insulin resistance and type 2 diabetes?	5
Translating guidelines into practice via implementation science: an update in lipidology	5
Remnant cholesterol as a new lipid-lowering target to reduce cardiovascular events	5
Dietary factors and brain health	5
Genetics of remnant cholesterol	5
Therapeutic application of genome editing in dyslipidemia	5

Proprotein convertase subtilisin/kexin type 9-inhibition across different patient populations	5
Resolution of apolipoprotein A1 and A2 proteoforms: their cardiometabolic correlates and implications for future research	5
Diagnosis of remnant hyperlipidaemia	5
Cholesterol 25-hydroxylase expression following immune activation in response to SARS-CoV-2 infection	4
Complex actions of sodium glucose transporter-2 inhibitors on lipids, calcific atherosclerosis, and bone density	4
Orticumab: the potential to harness oxidized LDL to reduce coronary inflammation with plaque-targeted therapy	4
Novel therapeutic opportunities for familial lecithin:cholesterol acyltransferase deficiency: promises and challenges	4
Inflammation in atherosclerosis: a Big Idea that has underperformed so far	4
Consensus and guidelines on lipoprotein(a) – seeing the forest through the trees	4
Established and potential cardiovascular risk factors in metabolic syndrome: Effect of bariatric surgery	4
Cholesteryl ester transfer protein inhibition: a pathway to reducing risk of morbidity and promoting longevity	4
Regulation of cardiovascular calcification by lipids and lipoproteins	4
Basic and translational evidence supporting the role of TM6SF2 in VLDL metabolism	4
Bempedoic acid for nonalcoholic fatty liver disease: evidence and mechanisms of action	4
Circulating cell-free DNA and its association with cardiovascular disease: what we know and future perspectives	4
Editorial introduction	4
Triglyceride-rich lipoprotein cholesterol and cardiovascular risk	4
Macrophage SR-B1 in atherosclerotic cardiovascular disease	3
PCSK9-directed therapies: an update	3
Increasing fruits and vegetables to reduce mortality and promote independence	3
Lipids and brain inflammation in APOE4-associated dementia	3
Fatty acid metabolism in cancer cells – the power of plasticity	3
Dyslipidemia and aortic valve disease	3
Bempedoic acid: new evidence and recommendations on use	3
Editorial introduction	3
Lipoprotein (a) in familial hypercholesterolaemia	3
G protein-coupled receptor 146: new insights from genetics and model systems	3
Proprotein convertase subtilisin/kexin type 9 as a drug target for abdominal aortic aneurysm	2
Familial combined hyperlipidemia is a polygenic trait	2
Angiopoietin-like 3 inhibition and the liver: less is more?	2
Quantification of high-density lipoprotein particle number by proton nuclear magnetic resonance: don’t believe the numbers	2
Updates on genetics and molecular biology	2
Cycling of metabolic states and metabolites as drivers of atherosclerosis	2
Ketogenic therapies in mild cognitive impairment and dementia	2
Management of familial hypercholesterolemia in pregnancy	2
Characteristics of plaque lipid-associated macrophages and their possible roles in the pathogenesis of atherosclerosis	2
Links between ceramides and cardiac function	2
Editorial introductions	2
Editorial introductions	2
Brain lipid metabolism: the emerging role of lipid droplets in glial cells	2
Lipidome and inflammation interplay: the role of diet in this relationship	2
Proprotein convertase subtilisin/kexin type 9 inhibition after acute coronary syndrome or prior myocardial infarction	2
Polygenic contribution for familial hypercholesterolemia (FH)	2